CERRITO MARIA GRAZIA

Ruolo: 
Tecnico - amministrativo
Telefono: 
0264488339
Stanza: 
U8, Piano: IV, Stanza: L4.6B
Via Cadore, 48 - 20900 MONZA

Pubblicazioni

  • Scagliotti, A., Grassilli, E., Cazzaniga, M., Capizzi, L., Lavitrano, M., & Cerrito, M. (2020). The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation. EUROPEAN JOURNAL OF CANCER, 138, S26. Dettaglio
  • Lavitrano, M., Farina, L., Cerrito, M., & Giovannoni, R. (2020). Sperm-Mediated Genetic Modifications. In M. Larson (a cura di), Transgenic Mouse : Methods and Protocols (pp. 125-132). Humana Press Inc.. Dettaglio
  • Lavitrano, M., Ianzano, L., Bonomo, S., Cialdella, A., Cerrito, M., Pisano, F., et al. (2020). BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. JOURNAL OF PATHOLOGY, 250(2), 134-147. Dettaglio
  • Formica, F., Mariani, S., D'Alessandro, S., Singh, G., Di Mauro, M., Cerrito, M., et al. (2020). Does additional coronary artery bypass grafting to aortic valve replacement in elderly patients affect the early and long-term outcome?. HEART AND VESSELS, 35(4), 487-501. Dettaglio
  • Giordano, F., Vaira, V., Cortinovis, D., Bonomo, S., Goedmakers, J., Brena, F., et al. (2019). p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 38(1). Dettaglio